HRP20220350T1 - Novi antimikrobni spoj - Google Patents
Novi antimikrobni spoj Download PDFInfo
- Publication number
- HRP20220350T1 HRP20220350T1 HRP20220350TT HRP20220350T HRP20220350T1 HR P20220350 T1 HRP20220350 T1 HR P20220350T1 HR P20220350T T HRP20220350T T HR P20220350TT HR P20220350 T HRP20220350 T HR P20220350T HR P20220350 T1 HRP20220350 T1 HR P20220350T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- bacterium
- bacteria
- compound according
- group
- Prior art date
Links
- 239000004599 antimicrobial Substances 0.000 title claims 2
- 241000894006 Bacteria Species 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 15
- 238000000034 method Methods 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 238000010839 reverse transcription Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000013535 sea water Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 238000000968 medical method and process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Spoj, koji ima strukturu prema formuli II
[image]
i njegove soli i solvati,
pri čemu je R1 atom halogena, odabran između klora, broma i joda, R2 i R3 su -O-CH3, R4 je -COOH, -C(O)OR5 i -C(O)NR5R6, i R5 i R6 su neovisno vodik, C1-C4-alkilna skupina, C2-C4-alkenilna skupina, C2-C4 alkinilna skupina i fenilna skupina.
2. Spoj prema zahtjevu 1, naznačen time što je struktura prema formuli III
[image]
i njegove soli i solvati.
3. Postupak za proizvodnju spoja prema zahtjevu 1 ili zahtjevu 2, koji sadrži sljedeće korake:
a) uzgoj bakterije odabrane iz skupine koju čine:
i) bakterijski izolat deponiran prema Budimpeštanskom ugovoru kod DSMZ-a dana 7. travnja 2016. godine pod brojem depozita DSM 32287; i
ii) bakterija koja je blisko srodna s bakterijskim izolatom i) kao što je bakterija sa sličnim genotipskim i/ili fenotipskim karakteristikama izoliranoj bakteriji;
u prikladnom mediju kulture koji sadrži morsku vodu;
b) ekstrahiranje spoja iz kulture.
4. Postupak prema zahtjevu 3, naznačen time što bakterija u svom genomu sadrži 16S rRNA koja reverznom transkripcijom i sintezom 2-og lanca daje sekvencu koja je najmanje 80% identična sekvenci prikazanoj u SEQ ID NO 1.
5. Postupak prema bilo kojem od zahtjeva 3 i 4, naznačen time što korak b) sadrži centrifugiranje kultiviranih bakterija čime se dobiva stanična peleta, iz koje se ekstrahira spoj.
6. Postupak prema bilo kojem od zahtjeva 3-5, naznačen time što se spoj ekstrahira iz stanične pelete uporabom dimetil sulfoksida (DMSO).
7. Postupak prema bilo kojem od zahtjeva 3-6, naznačen time što je medij kulture PM6, izborno sa umjetnom morskom vodom.
8. Uporaba izolirane bakterije za proizvodnju spoja prema zahtjevu 1 ili zahtjevu 2, naznačena time što je bakterija odabrana iz skupine koju čine:
a) bakterijski izolat deponiran prema Budimpeštanskom ugovoru kod DSMZ-a dana 7. travnja 2016. godine pod brojem depozita DSM 32287; i
b) bakterija koja je blisko srodna s bakterijskim izolatom a) kao što je bakterija sa sličnim genotipskim i/ili fenotipskim karakteristikama izoliranoj bakteriji.
9. Uporaba prema zahtjevu 8, naznačena time što blisko srodna bakterija u svom genomu sadrži 16S rRNA koja reverznom transkripcijom i sintezom 2-og lanca daje sekvencu koja je najmanje 80% identična sekvenci prikazanoj u SEQ ID NO 1.
10. Farmaceutski pripravak koji sadrži spoj prema zahtjevu 1 ili zahtjevu 2, i farmaceutski prihvatljiv jedan ili više nosača i/ili ekscipijenata.
11. Spoj prema zahtjevu 1 ili 2 za uporabu u terapiji.
12. Spoj prema zahtjevu 1 ili zahtjevu 2 za uporabu kao antimikrobno sredstvo.
13. Spoj za uporabu prema bilo kojem od zahtjeva 11-12, za liječenje bakterijske infekcije kod subjekta, koji sadrži davanje spoja prema zahtjevu 1 ili farmaceutskog pripravka prema zahtjevu 9 navedenom subjektu.
14. Spoj za uporabu prema zahtjevu 13, naznačen time što je bakterijska infekcija uzrokovana bakterijom otpornom na više lijekova.
15. Spoj za uporabu prema zahtjevu 14, naznačen time što je bakterijska infekcija uzrokovana Gram-pozitivnom ili Gram-negativnom bakterijom.
16. Ne-medicinski postupak za ubijanje ili inhibiciju rasta bakterije, koji sadrži korak dovođenja spoja prema zahtjevu 1 ili zahtjevu 2 ili pripravka prema zahtjevu 10 u kontakt s bakterijom koju treba ubiti ili inhibirati.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20160680A NO341815B1 (en) | 2016-04-22 | 2016-04-22 | New antimicrobial compound, a method of producing it, pharmaceutical compositions and uses in therapy |
| PCT/EP2017/059521 WO2017182632A1 (en) | 2016-04-22 | 2017-04-21 | New antimicrobial compound |
| EP17722393.0A EP3445766B1 (en) | 2016-04-22 | 2017-04-21 | New antimicrobial compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220350T1 true HRP20220350T1 (hr) | 2022-05-13 |
Family
ID=58692467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220350TT HRP20220350T1 (hr) | 2016-04-22 | 2017-04-21 | Novi antimikrobni spoj |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10494375B2 (hr) |
| EP (1) | EP3445766B1 (hr) |
| JP (1) | JP6964600B2 (hr) |
| CN (1) | CN109195971B (hr) |
| DK (1) | DK3445766T3 (hr) |
| ES (1) | ES2909248T3 (hr) |
| HR (1) | HRP20220350T1 (hr) |
| NO (1) | NO341815B1 (hr) |
| PL (1) | PL3445766T3 (hr) |
| PT (1) | PT3445766T (hr) |
| WO (1) | WO2017182632A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109280692A (zh) * | 2018-10-31 | 2019-01-29 | 广东药科大学 | 一种蜚蠊内生放线菌的抗真菌活性筛选方法及其发酵方法 |
| KR102112570B1 (ko) * | 2019-01-28 | 2020-05-19 | 한국해양과학기술원 | 신규 람노리피드 화합물 및 이의 용도 |
| CN109956951B (zh) * | 2019-04-11 | 2021-01-01 | 中国医学科学院医药生物技术研究所 | 鹿色霉素(cervinomycin)C1、C2、C3、C4及其生产方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494913A (en) * | 1994-12-13 | 1996-02-27 | Schering Corporation | Antifungal compounds |
| DE102006002427A1 (de) * | 2006-01-09 | 2007-07-12 | Combinature Biopharm Ag | Neue Lysolipin Derivate |
| WO2007095696A1 (en) * | 2006-02-27 | 2007-08-30 | The University Of Queensland | Polyketide xanthones and uses thereof |
-
2016
- 2016-04-22 NO NO20160680A patent/NO341815B1/en unknown
-
2017
- 2017-04-21 EP EP17722393.0A patent/EP3445766B1/en active Active
- 2017-04-21 PL PL17722393T patent/PL3445766T3/pl unknown
- 2017-04-21 PT PT177223930T patent/PT3445766T/pt unknown
- 2017-04-21 JP JP2018555117A patent/JP6964600B2/ja active Active
- 2017-04-21 HR HRP20220350TT patent/HRP20220350T1/hr unknown
- 2017-04-21 US US16/095,143 patent/US10494375B2/en active Active
- 2017-04-21 DK DK17722393.0T patent/DK3445766T3/da active
- 2017-04-21 ES ES17722393T patent/ES2909248T3/es active Active
- 2017-04-21 CN CN201780024990.4A patent/CN109195971B/zh active Active
- 2017-04-21 WO PCT/EP2017/059521 patent/WO2017182632A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| JP6964600B2 (ja) | 2021-11-10 |
| EP3445766A1 (en) | 2019-02-27 |
| CN109195971A (zh) | 2019-01-11 |
| EP3445766B1 (en) | 2021-12-15 |
| US10494375B2 (en) | 2019-12-03 |
| NO20160680A1 (en) | 2017-10-23 |
| JP2019521078A (ja) | 2019-07-25 |
| DK3445766T3 (da) | 2022-03-21 |
| CN109195971B (zh) | 2021-08-27 |
| WO2017182632A1 (en) | 2017-10-26 |
| US20190135822A1 (en) | 2019-05-09 |
| ES2909248T3 (es) | 2022-05-05 |
| PT3445766T (pt) | 2022-03-21 |
| NO341815B1 (en) | 2018-01-29 |
| PL3445766T3 (pl) | 2022-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dong et al. | Natural occurrence of edwardsiellosis caused by Edwardsiella ictaluri in farmed hybrid red tilapia (Oreochromis sp.) in Southeast Asia | |
| RU2020132171A (ru) | Новая бифидобактерия, характеризующаяся различными функциями, и ее применение | |
| HRP20220350T1 (hr) | Novi antimikrobni spoj | |
| Tan et al. | The bioprospecting of anti-Vibrio Streptomyces species: Prevalence and applications | |
| SI3209310T1 (en) | Compositions containing bacterial strains | |
| JP6826582B2 (ja) | 生物兵器防衛のためのミノサイクリン化合物 | |
| CN102317467B (zh) | 聚氨基聚酮化合物抗生素及其用途 | |
| US20220370526A1 (en) | Phage compositions comprising crispr-cas systems and methods of use thereof | |
| JP2019521078A5 (hr) | ||
| Okuda et al. | Type III secretion system genes of Edwardsiella tarda associated with intracellular replication and virulence in zebrafish | |
| Hamza et al. | Efficacy of cell free supernatant from Bacillus licheniformis in protecting Artemia salina against Vibrio alginolyticus and Pseudomonas gessardii | |
| KR20160047125A (ko) | 항바이러스 및 항병원성세균 활성을 가진 락토바실러스 프란타륨 Probio 090 및 이의 생산물 | |
| RU2011133824A (ru) | Фармацевтическая композиция для защиты животного от растройства, возникающего в результате инфекции бактерий, которая относится к группе нокардиоформных актиномицетов | |
| Boopathi et al. | Quorum quenching potentials of probiotic Enterococcus durans LAB38 against methicillin resistant Staphylococcus aureus | |
| US11478454B2 (en) | Methods to control infection using new generation small molecule growth inhibitors | |
| Jiang et al. | Isolation, identification, and biological control in vitro of tail rot pathogen strain from Hippocampus kuda | |
| Yang et al. | Bdellovibrio lyse multiple pathogenic bacteria and protect crucian carp Carassius auratus gibelio from Aeromonas veronii infections | |
| US20220389392A1 (en) | Crispr cas systems and lysogeny modules | |
| Abouelfetouh et al. | Investigation and treatment of fusidic acid resistance among methicillin-resistant staphylococcal isolates from Egypt | |
| Monir et al. | Pathogenesis of Aeromonas species in stinging catfish Shing (Heteropneustes fossilis) of Bangladesh | |
| MX2020008677A (es) | Novedoso bacteriofago de salmonella heidelberg sal-hep-1 y su uso para inhibir el crecimiento de las bacterias de salmonella heidelberg. | |
| Nayak et al. | A study on the effect of Bacillus spp. to control the pathogenic bacteria in aquaculture | |
| US10286019B2 (en) | Therapeutic bacteriophages | |
| Enany et al. | Antibacterial Activity of Bioactive Compounds from Endophytic Fungi against P. aeruginosa isolated from Freshwater Fishes | |
| Zhao | Characterization of the probiotic mechanism of Phaeobacter gallaeciensis S4 against bacterial pathogens |